Understanding and overcoming resistance to immunotherapy in genitourinary cancers

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–15. doi:10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• SEER*Explorer. An interactive website for SEER cancer statistics. 2023.
   Google Scholar
• Moreira M, Pobel C, Epaillard N, Simonaggio A, Oudard S, Vano Y-A. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resistance. 2020;3(3):454–471. doi:10.20517/cdr.2020.16.
   PubMedGoogle Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. doi:10.1126/scitranslmed.aad7118.
   PubMed Web of Science ®Google Scholar
• Shan J, Han D, Shen C, Lei Q, Zhang Y. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.1016646.
   Web of Science ®Google Scholar
• Said SS, Ibrahim WN. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics. 2023;15(4):1143. doi:10.3390/pharmaceutics15041143.
   PubMed Web of Science ®Google Scholar
• Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013; 19(2):393–403. doi:10.1158/1078-0432.CCR-12-1626.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, et al. Author correction: immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019; 25(6):1022. doi:10.1038/s41591-019-0449-8.
   PubMed Web of Science ®Google Scholar
• Miricescu D, Balan D, Tulin A, Stiru O, Vacaroiu I, Mihai D, Popa C, Papacocea R, Enyedi M, Sorin N, et al. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (review). Exp Ther Med. 2021; 21(5):540. doi:10.3892/etm.2021.9972.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li J, Wang Z, Zhao L, Qiu J, Xu Y, Wu G, Xia Q. Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis. Front Oncol. 2023;13:1077309. doi:10.3389/fonc.2023.1077309.
   PubMed Web of Science ®Google Scholar
• Mashhadi R, Pourmand G, Mehrsai A, Pakdel S, Dialameh H, Ahmadi A, Salem S, Salimi E, Mahboubi R. Effect of PTEN gene mutations and environmental risk factors on the progression and prognosis of bladder cancer. Iran J Public Health. 2014;43(1):56–61.
   PubMed Web of Science ®Google Scholar
• Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222–234. doi:10.1038/nrurol.2018.9.
   PubMed Web of Science ®Google Scholar
• Koushyar S, Meniel VS, Phesse TJ, Pearson HB. Exploring the wnt pathway as a therapeutic target for prostate cancer. Biomolecules. 2022;12(2):309. doi:10.3390/biom12020309.
   PubMed Web of Science ®Google Scholar
• Murillo-Garzón V, Kypta R. WNT signalling in prostate cancer. Nat Rev Urol. 2017;14(11):683–696. doi:10.1038/nrurol.2017.144.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen Q, Xu H. Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance. Discov Onc. 2021;12(1):40. doi:10.1007/s12672-021-00433-6.
   PubMedGoogle Scholar
• Wu G, Weng W, Xia P, Yan S, Zhong C, Xie L, Xie Y, Fan G. Wnt signalling pathway in bladder cancer. Cell Signal. 2021;79:109886. doi:10.1016/j.cellsig.2020.109886.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–235. doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016; 30(2):324–336. doi:10.1016/j.ccell.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31(1):563–604. doi:10.1146/annurev-immunol-020711-074950.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25(10):3074–3083. doi:10.1158/1078-0432.CCR-18-1942.
   PubMed Web of Science ®Google Scholar
• Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866. doi:10.3389/fimmu.2022.844866.
   PubMed Web of Science ®Google Scholar
• D’Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991;87(1):284–292. doi:10.1172/JCI114984.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017; 7(12):1420–1435. doi:10.1158/2159-8290.CD-17-0593.
   PubMed Web of Science ®Google Scholar
• Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2019; 75(5):846–852. doi:10.1016/j.eururo.2018.11.039.
   PubMed Web of Science ®Google Scholar
• Wilson JC, Furlano RI, Jick SS, Meier CR. A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease. J Gastroenterol. 2016;51(11):1050–1062. doi:10.1007/s00535-016-1199-8.
   PubMed Web of Science ®Google Scholar
• Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018; 111:122–128. doi:10.1016/j.urology.2017.08.039.
   PubMed Web of Science ®Google Scholar
• Huang P-Y, Yang Y-C, Wang C-I, Hsiao P-W, Chiang H-I, Chen T-W. Increase in akkermansiaceae in gut microbiota of prostate cancer-bearing mice. Int J Mol Sci. 2021;22(17):9626. doi:10.3390/ijms22179626.
   PubMed Web of Science ®Google Scholar
• Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Calì B, Attanasio G, Troisi J, Minini M, Mosole S, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021; 374(6564):216–224. doi:10.1126/science.abf8403.
   PubMed Web of Science ®Google Scholar
• Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 2018;21(4):539–548. doi:10.1038/s41391-018-0061-x.
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–5337. doi:10.1016/j.cell.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079–1084. doi:10.1126/science.aad1329.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018; 359(6371):91–97. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E, Ketelaars SLC, Cheng K, Vervier K, Shental N, et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. 2021; 592(7852):138–143. doi:10.1038/s41586-021-03368-8.
   PubMed Web of Science ®Google Scholar
• Sears CL, Pardoll DM. The intestinal microbiome influences checkpoint blockade. Nat Med. 2018;24(3):254–255. doi:10.1038/nm.4511.
   PubMed Web of Science ®Google Scholar
• Meza L, Feng M, Lee K, Sperandio R, Pal SK. The gut microbiome and metastatic renal cell carcinoma. J Clin Med. 2023;12(4):1502. doi:10.3390/jcm12041502.
   PubMed Web of Science ®Google Scholar
• Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, Segata N, Desnoyer A, Pietrantonio F, Ferrere G, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020; 78(2):195–206. doi:10.1016/j.eururo.2020.04.044.
   PubMed Web of Science ®Google Scholar
• Goubet A-G, Rouanne M, Derosa L, Kroemer G, Zitvogel L. From mucosal infection to successful cancer immunotherapy. Nat Rev Urol. 2023;20(11):682–700. doi:10.1038/s41585-023-00784-5.
   PubMed Web of Science ®Google Scholar
• Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D, et al. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nat Rev Urol. 2023; 20(12):706–718. doi:10.1038/s41585-023-00795-2.
   PubMed Web of Science ®Google Scholar
• Daud AI, Wolchok JD, Robert C, Hwu W-J, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, et al. Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016; 34(34):4102–4109. doi:10.1200/JCO.2016.67.2477.
   PubMed Web of Science ®Google Scholar
• Yin H, Harrison TA, Thomas SS, Sather CL, Koehne AL, Malen RC, Reedy AM, Wurscher MA, Hsu L, Phipps AI, et al. T cell-inflamed gene expression profile is associated with favorable disease-specific survival in non-hypermutated microsatellite-stable colorectal cancer patients. Cancer Med. 2023; 12(6):6583–6593. doi:10.1002/cam4.5429.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015; 372(21):2018–2028. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Yuan C, Liu Z, Yu Q, Wang X, Bian M, Yu Z, Yu J. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci Rep. 2019;9(1). doi:10.1038/s41598-019-50898-3.
   Google Scholar
• Lagos GG, Izar B, Rizvi NA. Beyond tumor PD-L1: emerging genomic biomarkers for checkpoint inhibitor immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40(40):e47–e57. doi:10.1200/EDBK_289967.
   Google Scholar
• Richard C, Fumet J-D, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, et al. Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients. Clin Cancer Res. 2019; 25(3):957–966. doi:10.1158/1078-0432.CCR-18-1940.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157. doi:10.1186/s40425-018-0479-7.
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6(1):35. doi:10.1186/s40425-018-0342-x.
   PubMedGoogle Scholar
• Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang S-P, Walsh AM, Baxi V, Pandya D, Baradet T, et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med. 2020; 26(5):688–692. doi:10.1038/s41591-020-0856-x.
   PubMed Web of Science ®Google Scholar
• Hirsch L, Flippot R, Escudier B, Albiges L. Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs. 2020;80(12):1169–1181. doi:10.1007/s40265-020-01327-7.
   PubMed Web of Science ®Google Scholar
• Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1000–1017. doi:10.2174/138945010791591395.
   PubMed Web of Science ®Google Scholar
• Han Z, Dong Y, Lu J, Yang F, Zheng Y, Yang H. Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application. Am J Cancer Res. 2021;11(8):3777–3793.
   PubMed Web of Science ®Google Scholar
• Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019;37(1). doi:10.1007/s12032-019-1329-2.
   PubMed Web of Science ®Google Scholar
• Cho H, Kaelin WG. Targeting HIF2 in clear cell renal cell carcinoma. Cold Spring Harb Symp Quant Biol. 2016;81:113–121. doi:10.1101/sqb.2016.81.030833.
   PubMedGoogle Scholar
• Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates Vascular Endothelial Growth Factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 2009;284(10):6038–6042. doi:10.1074/jbc.C800207200.
   PubMed Web of Science ®Google Scholar
• Kim J-H. Interleukin-8 in the tumor immune niche: lessons from comparative oncology. Adv Exp Med Biol. 2020;1240:25–33.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Varnier L, Pezzicoli G, Pirovano M, Cosmai L, Porta C. IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Front Oncol. 2022;12:990568. doi:10.3389/fonc.2022.990568.
   PubMedGoogle Scholar
• Najjar YG, Rayman P, Jia X, Pavicic PG, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2017; 23(9):2346–2355. doi:10.1158/1078-0432.CCR-15-1823.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33(5):949–955. doi:10.1093/carcin/bgs123.
   PubMed Web of Science ®Google Scholar
• Yuen KC, Liu L-F, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med. 2020; 26(5):693–698. doi:10.1038/s41591-020-0860-1.
   PubMed Web of Science ®Google Scholar
• Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N, Ogasawara K, Okumura K, Thomas DM, Smyth MJ, et al. IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun. 2017; 8(1):14607. doi:10.1038/ncomms14607.
   PubMedGoogle Scholar
• Kolodziejski T, Klein A, Nowacki M. Lymphography in the evaluation of various radical operations. Pol Tyg Lek. 1969;24(45):1727–1729.
   PubMedGoogle Scholar
• Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8(1):49. doi:10.1186/s40364-020-00228-x.
   PubMed Web of Science ®Google Scholar
• Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, et al. Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med. 2020; 26(12):1865–1877. doi:10.1038/s41591-020-1073-3.
   PubMed Web of Science ®Google Scholar
• Lu J, Xu W-H, Zhang H, Ye D. Editorial: the mechanism of tumor evolution and microenvironmental changes of genitourinary oncology in clinical diagnosis and treatment. Front Oncol. 2023;13:1272984. doi:10.3389/fonc.2023.1272984.
   PubMed Web of Science ®Google Scholar
• Derynck R, Turley SJ, Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9–34. doi:10.1038/s41571-020-0403-1.
   PubMed Web of Science ®Google Scholar
• Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M, Palomo-Ponce S, Tauriello DVF, Byrom D, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015; 47(4):320–329. doi:10.1038/ng.3225.
   PubMed Web of Science ®Google Scholar
• Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DMA, Haibe-Kains B, Karn T, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015; 75(21):4494–4503. doi:10.1158/0008-5472.CAN-14-3569.
   PubMed Web of Science ®Google Scholar
• Cao W, Ramakrishnan R, Tuyrin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, Johnson JJ, Min Zhang L, Klein-Seetharaman J, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014; 192(6):2920–2931. doi:10.4049/jimmunol.1302801.
   PubMed Web of Science ®Google Scholar
• Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, Ferris RL, Delgoffe GM. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45(2):374–388. doi:10.1016/j.immuni.2016.07.009.
   PubMed Web of Science ®Google Scholar
• Ye L-Y, Chen W, Bai X-L, Xu X-Y, Zhang Q, Xia X-F, Sun X, Li G-G, Hu Q-D, Fu Q-H, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016; 76(4):818–830. doi:10.1158/0008-5472.CAN-15-0977.
   PubMed Web of Science ®Google Scholar
• Henze A-T, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 2016;126(10):3672–3679. doi:10.1172/JCI84427.
   PubMed Web of Science ®Google Scholar
• Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. Cancer Res. 2011;71(16):5500–5511. doi:10.1158/0008-5472.CAN-11-0757.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Q. VHL and hypoxia signaling: beyond HIF in cancer. Biomedicines. 2018;6(1):35. doi:10.3390/biomedicines6010035.
   PubMed Web of Science ®Google Scholar
• Labrousse-Arias D, Martínez-Alonso E, Corral-Escariz M, Bienes-Martínez R, Berridy J, Serrano-Oviedo L, Conde E, García-Bermejo M-L, Giménez-Bachs JM, Salinas-Sánchez AS, et al. VHL promotes immune response against renal cell carcinoma via NF-κB–dependent regulation of VCAM-1. J Cell Biol. 2017; 216(3):835–847. doi:10.1083/jcb.201608024.
   PubMed Web of Science ®Google Scholar
• Brauch H, Weirich G, Brieger J, Glavac D, Rödl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000;60(7):1942–1948.
   PubMed Web of Science ®Google Scholar
• Yao M, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002; 94(20):1569–1575. doi:10.1093/jnci/94.20.1569.
   PubMedGoogle Scholar
• Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792–804. doi:10.1038/s41571-021-00546-5.
   PubMed Web of Science ®Google Scholar
• Ligorio M, Sil S, Malagon-Lopez J, Nieman LT, Misale S, Di Pilato M, Ebright RY, Karabacak MN, Kulkarni AS, Liu A, et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell. 2019; 178(1):160–175.e27. doi:10.1016/j.cell.2019.05.012.
   PubMed Web of Science ®Google Scholar
• Chang SS. Re: EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. J Urol. 2019;202:458. doi:10.1097/01.JU.0000569196.28580.f2.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212–20217. doi:10.1073/pnas.1320318110.
   PubMed Web of Science ®Google Scholar
• Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S. Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 2019;19(1):137. doi:10.1186/s12885-019-5353-6.
   PubMedGoogle Scholar
• Zhuang J, Shen L, Li M, Sun J, Hao J, Li J, Zhu Z, Ge S, Zhang D, Guo H, et al. Cancer-associated fibroblast–derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance. Cancer Res. 2023; 83(10):1611–1627. doi:10.1158/0008-5472.CAN-22-2213.
   PubMed Web of Science ®Google Scholar
• Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179(5):1177–1190.e13. doi:10.1016/j.cell.2019.10.029.
   PubMed Web of Science ®Google Scholar
• Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martínez L, Martínez-Saez E, Ramón y Cajal S, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018; 24(7):1024–1035. doi:10.1038/s41591-018-0044-4.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259–1271.e11. doi:10.1016/j.cell.2017.10.001.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151–167. doi:10.1038/s41571-018-0142-8.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016; 375(9):819–829. doi:10.1056/NEJMoa1604958.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409–413. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Ramelet AA, Walker-Nasir E. One daily application of oxiconazole cream is sufficient for treating dermatomycoses. Dermatologica. 1987;175(6):293–295. doi:10.1159/000248837.
   PubMedGoogle Scholar
• Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, Goldmann T. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression. Clin Epigenetics. 2017;9(1):51. doi:10.1186/s13148-017-0354-2.
   PubMed Web of Science ®Google Scholar
• Piper M, Kluger H, Ruppin E, Hu-Lieskovan S. Immune resistance mechanisms and the road to personalized immunotherapy. Am Soc Clin Oncol Educ Book. 2023;43(43):e390290. doi:10.1200/EDBK_390290.
   PubMedGoogle Scholar
• Snahnicanova Z, Kasubova I, Kalman M, Grendar M, Mikolajcik P, Gabonova E, Laca L, Caprnda M, Rodrigo L, Ciccocioppo R, et al. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer. Clin Exp Med. 2020; 20(1):87–95. doi:10.1007/s10238-019-00601-7.
   PubMed Web of Science ®Google Scholar
• Lorenzi S, Forloni M, Cifaldi L, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, et al. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One. 2012; 7(10):e46928. doi:10.1371/journal.pone.0046928.
   PubMed Web of Science ®Google Scholar
• Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, et al. microRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients. Gastroenterology. 2018; 155(3):784–798. doi:10.1053/j.gastro.2018.06.030.
   PubMed Web of Science ®Google Scholar
• Liu X-D, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020; 11(1):2135. doi:10.1038/s41467-020-15959-6.
   PubMed Web of Science ®Google Scholar
• Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168–179. doi:10.1016/j.canlet.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med. 2013; 210(9):1695–1710. doi:10.1084/jem.20130579.
   PubMed Web of Science ®Google Scholar
• Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011; 9(1):204. doi:10.1186/1479-5876-9-204.
   PubMedGoogle Scholar
• Ariafar A, Vahidi Y, Fakhimi M, Asadollahpour A, Erfani N, Faghih Z. Prognostic significance of CD4-positive regulatory T cells in tumor draining lymph nodes from patients with bladder cancer. Heliyon. 2020;6(12):e05556. doi:10.1016/j.heliyon.2020.e05556.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174. doi:10.1038/nri2506.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179(2):977–983. doi:10.4049/jimmunol.179.2.977.
   PubMed Web of Science ®Google Scholar
• Solito S, Falisi E, Diaz-Montero CM, Doni A, Pinton L, Rosato A, Francescato S, Basso G, Zanovello P, Onicescu G, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood. 2011; 118(8):2254–2265. doi:10.1182/blood-2010-12-325753.
   PubMed Web of Science ®Google Scholar
• De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016; 539(7629):443–447. doi:10.1038/nature20554.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, Woo G, Nguyen AV, Figueiredo CC, Foubert P, et al. PI3Kγ is a molecular switch that controls immune suppression. Nature. 2016; 539(7629):437–442. doi:10.1038/nature19834.
   PubMed Web of Science ®Google Scholar
• Xue J, Schmidt S, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel T, Emde M, Schmidleithner L, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014; 40(2):274–288. doi:10.1016/j.immuni.2014.01.006.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495–499. doi:10.1038/nature22396.
   PubMed Web of Science ®Google Scholar
• Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ, Weissleder R. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2(8):578–588. doi:10.1038/s41551-018-0236-8.
   PubMed Web of Science ®Google Scholar
• Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, et al. Myeloid cell–associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clin Cancer Res. 2021; 27(15):4287–4300. doi:10.1158/1078-0432.CCR-20-4574.
   PubMed Web of Science ®Google Scholar
• Han C, Deng Y, Xu W, Liu Z, Wang T, Wang S, Liu J, Liu X. The roles of tumor-associated macrophages in prostate cancer. J Oncol. 2022;2022:1–20. doi:10.1155/2022/8580043.
   Web of Science ®Google Scholar
• Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy. Cell. 2016; 167(2):397–404.e9. doi:10.1016/j.cell.2016.08.069.
   PubMed Web of Science ®Google Scholar
• Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013;1284(1):1–5. doi:10.1111/nyas.12105.
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017; 7(2):188–201. doi:10.1158/2159-8290.CD-16-1223.
   PubMed Web of Science ®Google Scholar
• Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, et al. Adaptive immunity in genitourinary cancers. Eur Urol Oncol. 2023; 6(3):263–272. doi:10.1016/j.euo.2023.03.002.
   PubMed Web of Science ®Google Scholar
• Cai Z, Chen J, Yu Z, Li H, Liu Z, Deng D, Liu J, Chen C, Zhang C, Ou Z, et al. BCAT2 shapes a noninflamed tumor microenvironment and induces resistance to Anti-PD-1/PD-L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity. Adv Sci. 2023;10(8). doi:10.1002/advs.202207155.
   Web of Science ®Google Scholar
• Lee YC, Lam H-M, Rosser C, Theodorescu D, Parks WC, Chan KS. The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol. 2022;19(9):515–533. doi:10.1038/s41585-022-00608-y.
   PubMed Web of Science ®Google Scholar
• Yu A, Hu J, Fu L, Huang G, Deng D, Zhang M, Wang Y, Shu G, Jing L, Li H, et al. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8 + T cell infiltration and functional transition. J Immunother Cancer. 2023; 11(10):7230. doi:10.1136/jitc-2023-007230.
   Web of Science ®Google Scholar
• Sakatani T, Kita Y, Fujimoto M, Sano T, Hamada A, Nakamura K, Takada H, Goto T, Sawada A, Akamatsu S, et al. IFN-Gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers Basel. 2022; 14(2):263. doi:10.3390/cancers14020263.
   PubMed Web of Science ®Google Scholar
• Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One. 2022;17(8):e0271339. doi:10.1371/journal.pone.0271339.
   PubMed Web of Science ®Google Scholar
• Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022; 28(4):704–712. doi:10.1038/s41591-022-01694-6.
   PubMed Web of Science ®Google Scholar
• Dizman N, Hsu J, Bergerot PG, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Med. 2021;10(1):79–86. doi:10.1002/cam4.3569.
   PubMed Web of Science ®Google Scholar
• Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, et al. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving Anti–PD-1 immune checkpoint inhibitors. Eur Urol. 2020; 78(4):498–502. doi:10.1016/j.eururo.2020.07.011.
   PubMed Web of Science ®Google Scholar
• Santoiemma PP, Powell DJ. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807–820. doi:10.1080/15384047.2015.1040960.
   PubMed Web of Science ®Google Scholar
• Kavanagh B, O’Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008;112(4):1175–1183. doi:10.1182/blood-2007-11-125435.
   PubMed Web of Science ®Google Scholar
• Yang G, Shen W, Zhang Y, Liu M, Zhang L, Liu Q, Lu HH, Bo J. Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer. Oncotarget. 2017;8(24):38378–38388. doi:10.18632/oncotarget.16386.
   PubMedGoogle Scholar
• Takeyama Y, Kato M, Tamada S, Azuma Y, Shimizu Y, Iguchi T, Yamasaki T, Gi M, Wanibuchi H, Nakatani T, et al. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer. Cancer Lett. 2020; 479:89–99. doi:10.1016/j.canlet.2020.03.013.
   PubMed Web of Science ®Google Scholar
• Ai L, Mu S, Wang Y, Wang H, Cai L, Li W, Hu Y. Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):1220. doi:10.1186/s12885-018-5086-y.
   PubMed Web of Science ®Google Scholar
• Slaney CY, Wang P, Darcy PK, Kershaw MH. Cars versus BiTEs: a comparison between T cell–redirection strategies for cancer treatment. Cancer Discov. 2018;8(8):924–934. doi:10.1158/2159-8290.CD-18-0297.
   PubMed Web of Science ®Google Scholar
• Shen Y, Eng JS, Fajardo F, Liang L, Li C, Collins P, Tedesco D, Nolan-Stevaux O. Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway. J Immunother Cancer. 2022;10(3):e004348. doi:10.1136/jitc-2021-004348.
   PubMed Web of Science ®Google Scholar
• Belmontes B, Sawant DV, Zhong W, Tan H, Kaul A, Aeffner F, O’Brien SA, Chun M, Noubade R, Eng J, et al. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors. Sci Transl Med. 2021;13(608). doi:10.1126/scitranslmed.abd1524.
   PubMed Web of Science ®Google Scholar
• Salas-Benito D, Berger TR, Maus MV. Stalled CARs: mechanisms of resistance to CAR T cell therapies. Annu Rev Cancer Biol. 2023;7(1):23–42. doi:10.1146/annurev-cancerbio-061421-012235.
   Google Scholar